AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03605992 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CentreRehab
Description: This intervention will last 12 weeks, with a total of 60 sessions: 24 supervised and 36 at home (to complete five exercise's sessions for week).
Study NCT01222364 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Cord Clamping
Description: Immediate clamping (\<5 seconds) of the umbilical cord after delivery.
Study NCT01222364 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed Cord Clamping
Description: Clamping of the umbilical cord at 30-45 seconds after birth.
Study NCT00380796 — intervention group
Intervention type: DRUG
Intervention: Collection of safety data for Cohort 1
Description: Twice-yearly collection of information about cancer incidence and cause of death among patients who participated in clinical trials of infliximab in the treatment of COPD. The follow-up period is 5 years.
Study NCT02000115 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portico transcatheter aortic valve
Description: St. Jude Medical transcatheter Portico aortic valve
Study NCT02000115 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available transcatheter aortic valve
Description: Commercially available transcatheter aortic valve
Study NCT00093730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-59926
Study NCT03043898 — intervention group
Intervention type: OTHER
Intervention: Lung sound transmission measurement
Description: Sound at chest wall is recorded using a sensor array during the bronchoscopy procedure, while a sound is played down the working channel of the bronchoscope.
Study NCT03043898 — intervention group
Intervention type: OTHER
Intervention: Lung sound recording
Description: Lung sounds are recorded using a sensor array.
Study NCT02995187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate tablet
Description: Apatinib 500 mg in tablet once daily
Study NCT01689155 — intervention group
Intervention type: BIOLOGICAL
Intervention: Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Description: 0.5 mL, Intramuscular
Study NCT03644043 — intervention group
Intervention type: DEVICE
Intervention: EEG scan
Description: WAVi EEG and evoked potential platform. Participants will be scanned using the ElectroCap (FDA Class II) and/or the WAVi Headset with the WAVi Co EEG P300 system, along with the structured clinical interviews and assessments for the various ailments or baseline screenings
Study NCT04664881 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartHeart Device
Description: A body-worn device that allows an individual to immediately transmit a 12-lead ECG from anywhere and anytime, using a smartphone application to a physician's office, hospital or monitoring center where designated on-call staff interpret the ECG and make recommendations.
Study NCT03945058 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TVS
Description: Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour daily for 4 weeks
Study NCT03945058 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TVS
Description: Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour daily for 4 weeks
Study NCT03945058 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM
Description: Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the earl lobule. Stimulator will be applied continuously for 1 hour daily for 4 weeks.
Study NCT03945058 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SHAM
Description: Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the earl lobule. Stimulator will be applied continuously for 1 hour daily for 4 weeks.
Study NCT01160640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Description: ceftrixone 250mg IM single dose
Study NCT01160640 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ceftriaxone
Description: ceftrixone 250mg IM single dose
Study NCT00898378 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: laboratory biomarker analysis
Study NCT00898378 — intervention group
Intervention type: OTHER
Intervention: liquid chromatography
Description: liquid chromatography
Study NCT00898378 — intervention group
Intervention type: OTHER
Intervention: mass spectrometry
Description: mass spectrometry
Study NCT00898378 — intervention group
Intervention type: OTHER
Intervention: questionnaire administration
Description: questionnaire administration
Study NCT04115293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zilucoplan (RA101495)
Description: Daily subcutaneous (SC) injection
Study NCT04115293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily subcutaneous (SC) injection
Study NCT03613597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide plus lobaplatin
Description: Thoracic intensity modulated radiation therapy (IMRT) + etoposide plus lobaplatin
Study NCT03613597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide plus cisplatin
Description: Thoracic intensity modulated radiation therapy (IMRT) + etoposide plus Cisplatin
Study NCT04541160 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CR
Description: Lung imaging evaluation performed with CR
Study NCT04541160 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ULDCT
Description: Lung imaging evaluation performed with ULDCT
Study NCT04063267 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E cigarettes
Description: Participants will be encouraged to substitute e-cigarettes for combustible cigarettes in order to reduce nicotine withdrawal symptoms
Study NCT04063267 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy
Description: Nicotine patches and gum to last them the first week based on their baseline recorded smoking. Participants will be advised to use both a 21 mg nicotine patch and 4 mg nicotine for cravings.
Study NCT02769676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3-week visit
Description: The intervention will be an additional visit to the usual postpartum care provider at 3-weeks postpartum.
Study NCT02769676 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: Participants in the usual care arm will receive no additional interventions.
Study NCT02753218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Study NCT02753218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 32731
Study NCT00504985 — intervention group
Intervention type: BEHAVIORAL
Intervention: Surveys
Description: 2 surveys, taking about 10-15 minutes each, during Emergency Center visit
Study NCT03880604 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Triple tourniquets
Description: A number 1 polyglactin suture was tied around the cervix to occlude the uterine arteries, and polythene tourniquets were tied around the infundibulopelvic ligament to obstruct the ovarian vessels
Study NCT03880604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TA
Description: 1-gram tranexamic acid (10 ml) in 100 ml saline infusion
Study NCT03880604 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo to TA
Description: placebo to 1-gram tranexamic acid (10 ml) in 100 ml saline infusion
Study NCT01553032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erbitux®
Description: 400mg/m2 initial dose, followed by weekly doses of 250mg/m2 Treatment duration: 7-8 weeks
Study NCT01553032 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Fractionated Radiotherapy
Description: 30-35 fractions of radiotherapy (6-7 weeks)
Study NCT02363283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glembatumumab Vedotin
Description: Given IV
Study NCT02363283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01444352 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine Formulation 1
Description: 0.5 mL, Intramuscular (Low dose)
Study NCT01444352 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine Formulation 2
Description: 0.5 mL, Intramuscular (Middle dose)
Study NCT01444352 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine Formulation 3
Description: 0.5 mL, Intramuscular (High dose)
Study NCT02363283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01444352 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL, Intramuscular
Study NCT02030054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Patients were randomly assigned to atorvastatin (40 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
Study NCT02030054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Patients were randomly assigned to rosuvastatin (20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
Study NCT02375711 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: A blood sample of 35 ml is achieved at 1 month to evaluate the anti-HBV cell response. Two other blood samples of 10 ml are scheduled 3 and 6 months after vaccination to assess humoral response to HBV vaccination.
Study NCT04148755 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic ultrasound guided fine needle aspirate
Description: All patients are going to have an EUS guided elastography with FNA of solid pancreatic lesions
Study NCT01882829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dextromethorphan/quinidine
Description: up to 45/10 mg every 12 hours in patients with TRD with a short 7 day tapering period in which subjects are tapered off 45/10 mg dose from twice a day to once daily for an additional 7 days at post 8-week treatment period to minimize the potential for discontinuation effects
Study NCT01100580 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low salt diet
Description: Daily salt intake less than 4 g/day
Study NCT01100580 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: water therapy
Description: abundant intake of water with a low mineral and low sodium content (at least 2 litres in winter and 3 in summer).
Study NCT03453515 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEART
Description: Interactive web-based intervention with five modules: motivation, knowledge, attitudes/norms, self-efficacy, and sexual communication skills.
Study NCT03453515 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Growing Minds
Description: Interactive web-based intervention with five modules: mindsets introduction, growth mindsets of intelligence, growth mindsets of self-control, growth mindsets of people, and integrative summary.
Study NCT02673060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBC-11
Description: 0.5 mg/kg-10 mg/kg , IV (in the vein) on day 1-5 of each 28 day cycle. Number of cycles: 2, in case of partial metabolic reaction or stable metabolic reaction - up to 4.
Study NCT02500966 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DUDA device
Description: Insertion DUDA device
Study NCT02500966 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LEEP
Description: Loop Electrosurgical Excision Procedure
Study NCT04565184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine combination
Description: Artesunate-amodiaquine (Coarsucam®: Sanofi-Aventis, France) is co-packaged as artesunate 50 mg and amodiaquine hydrochloride USP equivalent to amodiaquine base of 153.1 mg. Each child shall be given one, two or three tablets depending on the weight.
Study NCT04565184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether, Lumefantrine Drug Combination
Description: Artemether-lumefantrine (Coartem®: Novartis, Switzerland) is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains two blisters for each day with one, two or three tablets depending on the weight of the child
Study NCT03708627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost Ophthalmic
Description: Bimatoprost, aka Lumigan, one drop in one eye nightly
Study NCT01410539 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT guided PCI
Description: OCT guided PCI. Only thrombectomy in case of negative OCT findings (other than uncovered struts).
Study NCT01410539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OCT guided medical therapy
Description: OCT guided medical therapy. Tailored antiplatelet therapy.
Study NCT02913040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula
Description: Oxygen delivery through Heated Humidified High Flow Nasal Cannula
Study NCT02500966 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LEEP
Description: Loop Electrosurgical Excision Procedure
Study NCT04125758 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Description: Brief audio recordings discussing mindfulness or guided mindfulness practices.
Study NCT04125758 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tracking time spent on mobile device
Description: Participants will record each day how much time they estimate they spent on their smart phone in the past 24 hours.
Study NCT02534623 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia
Study NCT02534623 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Study NCT02534623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Study NCT02534623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Study NCT02534623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Study NCT02534623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane
Study NCT01729429 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV brochure, recall, reminders
Description: * HPV-vaccine specific brochure mailed before clinic visit~* Telephone recalls after visit for those who complete pre-clinic survey and decline the vaccine~* Telephone reminders for those who complete the pre-clinic survey and are late for receiving the 2nd and/or 3 doses
Study NCT01729429 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Adolescent Vaccine Brochure
Description: Participants were mailed a brochure describing the 4 recommended adolescent vaccines (HPV, meningococcal, tetanus diptheria acellular pertussis (TDAP), and influenza) 1-2 weeks before a clinic visit
Study NCT01832038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Strength: Lacosamide (LCM) 50 mg, LCM 100 mg~Formulation: Tablet~Frequency: twice daily during the study period (until the date of approval)~At the completion of EP0008 \[NCT01710657\], all subjects who choose to enroll in EP0009 will be taking a dose of Lacosamide 200 mg/day. At the beginning of EP0009, the investigator may maintain the LCM dose or increase or decrease the dose. During the Treatment Period, the investigator will be allowed to increase or decrease the dose of LCM to optimize tolerability and seizure reduction. The LCM dose may be decreased to 100 mg/day or increased, no faster than 100 mg/day per week, up to 400 mg/day.
Study NCT03211858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: SAR341402 100 units per milliliters (U/mL) (dose range of 1 unit to 80 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2-hour postprandial plasma glucose (PPG \<10 millimoles/liter \[mmol/L\] \[\<180 milligram/deciliter {mg/dL}\]) while avoiding hypoglycemia.
Study NCT02913040 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Flow Nasal Prongs
Description: Oxygen delivery through Low Flow Nasal Prongs
Study NCT02160353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate, Prednisolone
Study NCT02803762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: 400 mg \[14C\]pacritinib (containing 100 μCi radioactivity) administered orally as a single dose following at least a 10-hour fast (not including water) on Day 1
Study NCT00772083 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational brochure
Description: This brochure will educate anemic blood donors regarding the possible causes of their anemia, and based on age will make recommendations for who should seek consultation with a physician.
Study NCT00772083 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard pamphlet
Description: The BloodCenter of Wisconsin's default action when a potential donor has been found to be anemic is to provide a standard pamphlet with very basic nutritional information.
Study NCT00415454 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Ad5-yCD/mutTKSR39rep-ADP
Description: Single injection on day 1 at one of five dose levels
Study NCT01406925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Placebo cream
Study NCT01406925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL001 cream
Description: Cream for single-dose intra-anal application
Study NCT00174291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin
Description: Liquid, daily to final height Maximum Dosage: 50 µg/kg/day
Study NCT04158791 — intervention group
Intervention type: PROCEDURE
Intervention: pars plana vitrectomy with epimacular membrane removal and internal limiting membrane peeling
Description: 25-gauge pars plana vitrectomy with a solution of 0.15% trypan blue, 0.025% brilliant blue G, 4% polyethylene glycol (MembraneBlue Dual) assisted ERM/ILM removal performed by a single surgeon (GV); no air-fluid exchange was performed during surgery. In phakic eyes, phacoemulsification with intraocular lens implantation was performed at the time of vitrectomy.
Study NCT01160640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Doxycycline 100 mg PO bid x 14 days
Study NCT01160640 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxycycline
Description: Doxycycline 100 mg PO bid x 14 days
Study NCT01160640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: metronidazole 500 mg PO bid x 14 days
Study NCT01160640 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: placebo oral capsule PO bid x 14 days
Study NCT01833169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: BKM120 100 mg (oral gelatine capsules) was administered orally once daily starting from cycle 1 day 1 and will be dosed continuously every day for each 28-day cycle
Study NCT02357927 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mini-AFTERc
Description: 20-30 minute structured conversation following guidelines and instruction within the Mini-AFTERc 20 page manual
Study NCT01526122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G0041(75/100mg)
Description: G0041(75/100mg) 2 capsules(Clopidogrel 75mg \& Aspirin 100mg in 1 capsule), PO
Study NCT02357927 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: telephone call
Description: this consists of a 20-30 minute conversation about the general well-being of the patient with no specific reference to recurrence fears unless raised by the patient explicitly themselves
Study NCT04870164 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One administration at day 1 by infusion.
Study NCT01526122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel & Aspirin
Description: Clopidogrel 75mg 2 tablets \& Aspirin 100mg 2 capsules, PO
Study NCT00519779 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 supplementation
Description: 2.5 g/day omega-3
Study NCT00519779 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oral omega-3 fish oil placebo
Description: to match experimental dosage
Study NCT04949685 — intervention group
Intervention type: PROCEDURE
Intervention: plantar plate repair
Description: surgical repair via dorsal approach of lesser metatarsophalangeal joint general anesthesia
Study NCT03845764 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Rapid on-site evaluation
Description: Specimens obtained with endoscopic sampling procedures are stained with a rapid method (i.e., Diff Qui) and submitted to on-site cytologic review
Study NCT05108051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273
Description: ZSP1273 tablets 600mg administered orally once daily